TW199098B - - Google Patents
Download PDFInfo
- Publication number
- TW199098B TW199098B TW079108273A TW79108273A TW199098B TW 199098 B TW199098 B TW 199098B TW 079108273 A TW079108273 A TW 079108273A TW 79108273 A TW79108273 A TW 79108273A TW 199098 B TW199098 B TW 199098B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- substituted
- phenyl
- benzyl
- ministry
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- -1 6-0-methylerythromycin A oxime Chemical class 0.000 claims abstract description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 15
- 125000005843 halogen group Chemical group 0.000 claims abstract description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 9
- 125000005504 styryl group Chemical group 0.000 claims abstract description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 4
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract 2
- 238000011049 filling Methods 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000007789 gas Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims 2
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract description 5
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract description 4
- 229960003276 erythromycin Drugs 0.000 abstract description 3
- 125000003545 alkoxy group Chemical group 0.000 abstract description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 abstract description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000005543 phthalimide group Chemical group 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 102000003951 Erythropoietin Human genes 0.000 description 9
- 108090000394 Erythropoietin Proteins 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 229940105423 erythropoietin Drugs 0.000 description 9
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 150000002923 oximes Chemical class 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101150046236 CNR1 gene Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229960005224 roxithromycin Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UJPMYEOUBPIPHQ-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical group CC(F)(F)F UJPMYEOUBPIPHQ-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- CRRUGYDDEMGVDY-UHFFFAOYSA-N 1-bromoethylbenzene Chemical compound CC(Br)C1=CC=CC=C1 CRRUGYDDEMGVDY-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KXVSPXCGTNISAP-UHFFFAOYSA-N 4-bromo-3-oxobutanoyl bromide Chemical compound BrCC(=O)CC(Br)=O KXVSPXCGTNISAP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical class COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000009660 Sassafras variifolium Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ZDVDCDLBOLSVGM-UHFFFAOYSA-N [chloro(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(Cl)C1=CC=CC=C1 ZDVDCDLBOLSVGM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000005427 anthranyl group Chemical group 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108010046435 cholecystokinin-J Proteins 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000008252 erythrosides Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
vmm. B6 經濟部屮央標準::工消费合作社卬^ 五、發明説明(1 ) 發明背景 (1 )發明範圍 本發明是有關新穎的抗生素红徽素衍生物,持言之是 有關新穎的6 — 0 -甲基紅徽素A 9 —肟衍生物及其鹽 類,具有拮抗红徽素抗性細菌強的抗菌活性。 (2 )先前技藝 紅徽素A是一種抗生素,其在臨床上廣泛地當做感染 性疾病之治療劑,如由許多革蘭氏陽性細菌,某些革蘭氏 陰性細菌及徽漿菌所引起之感染性疾病。紅徽素A的主要 缺點為酸穩定性很低,如此使口服趿收率低且不一致。在 革蘭氏陽性細菌中已知有.些細菌對紅徽素A之敏感性低於 其他病原《,且耐受紅黴素。為了改進红徽素此種生物及 藥物動力特性,已製成許多衍生物。例如,於美國專利第 4 , 3 4 9 , 5 4 6中掲示之紅徽.素9 -肟醚衍生物,於 美國專利第4, 331, 803及4, 680, 386及 E. P.專利第245, 013中所掲示之6-0—甲基 红徽素衍生物。 上述之衍生物可適度地解決酸穩定性難題,此為红徽 素的一個缺點。因此,這些衍生物當口服時可較紅徽素有 更佳之活體内抗菌活性。然而拮抗紅徽素A之耐受菌問題 仍未充份解決。 另一方面,E. P.專利第194,833號是有關 一糸列6 — 〇 —甲基红徽素9 —肟®f衍生物。然而,此專 本紙张尺度逍用中國S家標準(CNS)T4規格(210X297公犮) -4 - (請先閱讀背面之注意事項再填寫本頁} i990S8 A6 _____B6 _ 五、發明说明(2 ) 利只掲示於操作實例中之甲基醚衍生物,但對於拮抗紅徽 素耐受細菌之活性根本未報告。 本發明者已發現某些6-0-甲基紅徽素A 9-肟 衍生物,對拮抗紅徽素耐受細菌有強的抗菌活性,且因而 完成本發明。 發明要點 本發明之主題是提供6-0_甲基紅徽素A 9-肟 衍生物,由下式代表 {請先閱讀背面之注意事項再填寫本貫)
經濟部中央棣準局印裝 其中X是苄基,在其苯環上被選自下列1至5成負基圃所 取代·•鹵原子,C^5烷基、硝基、三氣甲基、苯基、笮 基、苯乙烯基、2 -氣苄氣基、3 - (4~氣苯基)一 1 ,2 4-嗒二唑-5 -基及2-甲氣羰基窄醯基;經1至 3個硝基取代之苯基;α -甲基窄基;α~甲基苯乙基; 二苯甲基;三苯甲基;二苯駢環庚烷基;下式基圍一( 甲 4(210Χ 297公寿)_______ - 5 - 199098 A6 B6 經濟部中喪搮準扃印处♦ 五、發明說明(3 ) CH2 ) „ -R (其中R是苯基、苯硫基、被鹵原子取代 之苯硫基、C5-6之環烷基、某基;葸基、喹啉基、苯乙 烯基、正葙基、5 -氣- 2 _睡噍基、2 -苄氧羰基胺基 噻唑一 4 —基,酞醯亞胺基、9_溴_9_葙基、1 一烷 氧羰基甲基D引跺一 3 -基,其中為烷氧基、4一 ( 吡啶-2 -基)哌嗪基或被1或2成員選自鹵原子所取代 的吡啶基及2,2,2_三氟乙氣基,且η為1至6之整 數),¥是氫原子,經硝基取代之苯基,或2-胺基瞜唑 - 4 -基甲羰基,及其藥學上可接受之鹽類。 發明之詳細說明 於本發明中,C:-5烷基像指拮直或分支之烷基*如 甲基、乙基、丙基、異丙基、丁基及第三、丁基。 烷氣基為1 -烷氣羰基甲基°引跺- 3 -基之部份,偽指甲 氧基、乙氧基及異丙氣基。鹵原子條指氟原子、氣原子、 溴原子及碘原子。 本發明藥學上可接受之鹽類包括與酸形成之鹽,酸如氫 氣酸、氫溴酸、硫酸、磷酸、甲酸、醋酸、丙酸、丁酸、 檸樣酸、乙醇酸、乳酸、酒石酸、蘋果酸、馬來酸、延胡 索酸、葡萄糖酸、草酸、硬脂酸、杏仁酸、硫氮酸、苯甲 酸、琥珀酸、對位甲苯磺酸、苯磺酸、甲烷磺酸、月桂基 磺酸、天冬胺酸、穀胺酸、己二酸、半胱胺酸、菸鹼酸、 丙烯酸聚合物及羧乙烯基聚合物。 本發明的式I化合物呈現二個異構物(E-及Z -型 (請先聞讀背面之注意事項再填寫本頁) •裝· •打· •綠. 'f 4(210Χ ‘297公辞) 199098 經 濟 部 中 央 搮 準 局 印 裝 A6 __B6 五、發明说明(4 > ),偽衍自P-肟基圍。本發明並不限於二種異構物之一 ,但以E-型為較佳。 在本發明較佳化合物中,為式I其中X為苄基而在苯 環上被烷基或鹵原子所取代,式-(CH2) „—R 基團(其中R為Μ基且η是1至3的整數)◊最佳之化合 物為其中X是葸甲基,2,4,6 -二甲基苄基及4 一 ( 第三,丁基)苄基。 本發明化合物之製備可如下: 6 - 0_甲基红徽素A 9 -肟(由美國專利第4, 6 8 0,3 8 6號中得知)溶於適當的有機溶劑中,再於 鹼存在下與式X- 2化合物反應(其中X如上所定義,且 j Z為鹵原子)可生成有良好産迕之式I化合物。此處所用 之適當有機溶劑意指:丙酮、四氫呋喃、N,N-二甲替 甲醛胺、二甲亞砚、及其混合物◊驗係指如:氫化鈉、氫 氧化鈉及氫氧化鉀。反應溫度由- 2 0至5 0 - °C,最好 是 0 - 2 5 *C。 本發明化合物對於拮抗革蘭氏-陽性及革蘭氏-陰性 細菌有強的抗菌活性,包括紅徽素A耐受蘭在内,且因此 可當做抗菌劑用於治療人類及動物(包括農場動物)之細 菌性感染。 針對此目的,本發明化合物可口服或腸外投藥,呈如 錠劑、膠囊劑、散劑、糖錠、油膏、懸液劑、栓劑及注射 溶液劑之劑量型式,其均可依據習知之藥學操作製備。 式I化合物於成人之每天劑量可達每天約5 0 - (請先《讀背面之注意事項再填寫本|1> 甲(?10X 297y -7 - 199098 A6 B6 烛濟部中夹螵準Λ印嚷 五、發明説明(5 ) 3 0 0 0毫克,呈單一或達三次之多的分別劑置。 式I化合物是低毒性。口服時之L 05。值 > 在老鼠為 2 〇 〇 〇毫克/公斤以上。 實驗〔活體外抗菌活性〕 本發明化合物拮抗各種受試細菌之活體外抗菌活性, 可由瓊脂稀釋技術來偵測,以敏感試驗瓊脂(Eiken)為試 驗培養基,依據日本化學治療學會指定Μ I C方法而行。 比較用藥物使用:紅徽素A、6 - 0 -甲基紅徽素a ’紅徽素A 9 —甲氧基乙氧基甲后(roxithromycin若 西素徽素)及6-0_甲基紅徽素A 9-甲肟。 結果以Μ I C值示出(對微生物之最小抑制濃度,毫 克/毫升),示於表1。 表I中受試藥物之符號表示以下化合物。 a ;紅徽素A b;6-0-甲基紅徽素A c;若西素徽素 d;6-0-甲基紅徽素A 9-甲B A;下述實例中之7號化合物 B;下述實例中之2號化合物 C ;下述實例中之3 5號化合物 D ;下述實例中之4號化合物 E ·,下述實例中之8號化合物 F;下述實例中之1號化合物 {請先閱讀背面之注意事項再填寫本页) f 4(210X 297 -8 199088 A6 B6 五、發明説明(6 ) G ;下述實例中之5 6號化合物 Η ;下述實例中之5 5號化合物 I;下述實例中之45號化合物 {請先閱讀背面之注意事項再填寫本頁) •装· •打· •線· 經濟部中央抹準局印裝 -9 - 甲 4(210X297公;* 199098 A6 B6 五、發明说明(7 )表1 活髏外抗菌活性M 1C值(毫克/毫升) 級濟部中央樣準局印裝 細菌 受試藥物 金黃色葡萄球菌 J-109 金黃色葡萄球菌 B1 a >100 >100 b >100 >100 c >100 >100 d >100 >100 A 6.25 6.25 B 6.25 6.25 C 25 50 D 12.5 12.5 E 12.5 12.5 F 6.25 6.25 G 25 25 H 12.5 12.5 I 12.5 12.5 {請先聞讀背面之注意事項再填寫本頁) •裝♦ .訂· •綠· 本發明由以下實例更詳細説明。實例1至7示出本發 明化合物,利用典型製備法a至g獲得,且表2列出本發 f 4(210X 297^:^) ___~ 10 ~ 199088 A6 B6 五、發明説明(8 ) 明化合物,其物理特性及製法。 實例1 (製法a ) 製備6 - 〇-甲基紅徽素A 9 -〔0 - (2,4,6-三甲基苄基)肟〕 對6-0-甲基紅徽素A 9_甲肟(1克,1. 3 1毫莫耳)於四氫呋喃(2 0毫升)之溶液,加入四丁基 銨化碩(25毫克,0.07毫莫耳),2,4,6 -三 甲基苄基氛(33 1毫克,1. 96毫莫耳)及85%氫 氣化鉀粉末(103毫克,1. 56毫莫耳),混合物在 室溫度下攪拌2 0小時。反應混合物以乙酸乙酯萃取,乙 酸乙酯層再以飽和的氛化鈉水溶液洗滌並於無水硫酸鎂上 乾燥。乙酸乙酯減壓蒸發,殘留物以矽膠管柱層析純化( 溶離劑;氣仿:甲醇:氨=19:1:0.1)可得81 3毫克的標題化合物(1號化合物)呈白色晶狀粉末。 賁例2 (製法b ) 製備6 — 0 -甲基紅徽素A 9_〔0; (α -甲基苄基 )肟〕 雉濟部中央详率扃印裝 {請先聞績背面之注意事項再填寫本頁) 將6-0 -甲基紅徽素A 9 -甲肟(1克,1. 31 毫莫耳),α —甲基苄基溴(0. 54毫升,3. 93毫 某耳),85%氫氣化鉀粉末(103毫克,1. 56毫 某耳)及Ν,Ν -二甲替甲醯胺(2 0毫升)之混合物於 冰冷卻下搜拌2 . 5小時。之後依循實例1中相似之操作 f 4(210Χ 297-i:^)__- 11 ~ ____ 199098 A6 B6 經濟部中央梯準扃印¾ 五、發明説明(9 ) ,可得7 3 0毫克標題化合物(4號化合物)呈白色泡沫狀。 實例3 (製法c ) 製備6-0 —甲基紅徽素A 9 -〔0 —二苯甲基)肟〕 將6-0 -甲基紅徽素A 9 -涉肟(2克, 2. 6 2毫莫耳),於N,N-二甲替甲醯胺(4 0毫升 )之溶液,在冰冷卻下加入二苯基甲基氯(1. 4毫升, 7· 8 7毫莫耳)及6 0%氫化鈉(1 5 8毫克, 3. 95毫莫耳),且混合物在室溫下攪拌7小時。之後 依循實例1相似萃取及純化,可得7 2 0毫克檫題化合物 (9號化合物)呈白色泡沫狀。 實例4 (製法d ) 製備6 — 0 -甲基紅徽素A 9 —〔〇 - (2 -硝基苯基 )肟〕(a)及 4"-0-(2 -硝基苯基)—6 - 0 — 甲基紅徽素A 9-〔0_(2_硝基苯基)肟〕(b) 將6 - 0-甲基紅徽素A 9 -肟(5. 33克,7 毫莫耳)於二噁烷(8 0毫升)之溶液,在冰冷卻下加入 2 —氟硝基苯(1. 1毫升,10. 5毫莫耳)及60% 氫化納(3 3 6毫克,8· 4毫莫耳)且混合物在室溫下 搜拌2小時◊之後依循實例1相似的萃取,分離及純化, 可得3 · 9 2克的標題化合物(a ) 〔 2 7 ( a )號化合 物〕,及730毫克標題化合物(b) 〔27 (b)號化 {請先聞讀背面之注意事項再填寫本页) •裝· .訂. .線. 甲 4(2l〇x 297乂兮}_ -12 - 199088 A6 B6 域滴部中决嫖準局印5<· 五、發明说明(10 ) 合物〕,各自為白色泡沫狀。 實例5 (製法e ) 製備6-0 -甲基紅徽素A 9 -〔〇 —(三苯甲基)后 3 對6 - 0-甲基紅撇素A 9 -肟(2克,2. 62 毫莫耳)於N,N —二甲替甲醯胺(2 0毫升)之溶液, 加入三苯甲基氯(1· 1克,5. 2 4毫莫耳)及三乙胺 (2毫升,14· 35毫莫耳),混合物在室溫下攪拌6 小時。之後,依循實例1相似的萃取及純化,可得6 0毫 克的標ή化合物(4 0號化合物)呈白色泡沫狀。 實例6 (製法f ) 製備6 — 0—甲基紅徽素A 9-〔0 - (2_笮氣羰基 胺基睡唑-4 -基甲基)肟〕 將6 — 0-甲基紅徽素A 9-肟(3克,3. 93 毫莫耳)於四氫呋喃(5 0毫升)之溶液,加入2 -苄氧 羰基胺基_ 4 —氯甲基瞎唑(1 . 2毫克,4 . 2毫莫耳 )、四丁基銨化碘(144毫克,0. 39毫莫耳)及 6 0%氫化鈉(4 7 2毫克,11. 8毫莫耳)。依循實 例1之相似步驟,可得1. 12克標題化合物(4 1號化 合物)呈淺黃色泡沫^ 實例7 (製法g ) {請先閱讀背面之注意事項再填寫本页) .¾. •打· •線· 甲 4(210X 297公泠) -13 - 199088 A6 _B6 五、發明说明(11 ) 製備4" - 0 - (2 —胺基ί*唑—4 -基)甲羰基一 6 -〇 -甲基紅徽素A 9-〔0 - (2,4,6-三甲基笮 基)肟〕 對實例1所得化合物(4 4 7毫克,0. 5毫莫耳) 於二氣甲烷(5毫升)之溶液,在_7 0eC下加入碩酸氫 鈉(8 4毫克,1毫莫耳)及溴乙醯乙醯基溴(1 2 2毫 克,0. 5毫莫耳),混合物在-7 0 °C下攪拌5分鐘, 再於室溫下3 0分鐘。二氣甲烷於減壓下蒸發後,殘留物 溶於N,N -二甲基乙醯胺(5毫升),對之加入硫脲( 7 6毫克,1.〇毫莫耳),混合物再於室溫下攪拌17 小時。反應溶液以乙酸乙酯萃取,再以飽和的氣化鈉水溶 液洗滌,且乙醯乙酯層置無水硫酸鎂上乾燥。乙酸乙酯於 減壓下蒸發,殘留物以矽膠管柱層析純化(溶離劑:氣仿 :甲醇:氨=95:5:0.1)可得170毫克的標題 化合物(4 4號化合物)呈橘黃色泡沫狀。 t請先聞讀背面之注意事項再填寫本页) k· •打· 經濟部中央棣準局印裝 千4(210乂 297公角) -14 - 199088 A6 B6 五、發明説明(12) 經濟部中央橾準局印装 H-1 化合物 編號 1 -C丨丨2"~^—‘1 丨丨 9 _ti 1 .o -Q ¢-3 CN3 O v r\ rf-X. X 工 f 1. 32(911, s) 2. 28(011, s) 3. 05(311, s) 3. 33(311. s) 4. 03(111, s) 4. 9ϋ. 5. 00(211, ΛΙΙη) 7. 20. 7. 30, 7. 3G. 7. 40(411) Own-^tocorororo C3〇cr)COOC〇r〇CN3 -s- cn o *— cc in cc re \ S. /»—s y-\ N /--s /·—N C<〇 CO CO CxC CT> CO *W^ 〇·»_✓ Nw>· M-I-NIVIRiCDCjPa) 〇'(ppm) m_p. 13卜 14「C (ΘΦ醉中W結晶) 質贵(FAB) m/z ; 909Π1ΙΙ〕'- m. i)· 198〜202Ό (自乙酸乙δϋ中再結晶) 5¾ 贵(FAB) ra/z ; 895CH1I)' 除HNMR外之 物理待性 P P mm
0 2 ......................................................¾..............................乜.............................媒 {請先《讀背面之注意事項再填K本页) -15 - 甲 4(210X 297 公辞) 199088
A B 13 明 说 明 發 五 6
3 lc=2
{請先聞讀背面之注意事項再填薄本页) _裝·
II Η 谢 3S1U) 9SI1. S) 31(31u) mill's) 3G, 5.4-1(211. ABq.vllllz) 22. 7. 2G- 7· 34, 7. 38(=) p— CT^ CO CO ΓΌ cn ^ co C3 )/>—N *v /-~"N ( C«0 C_O s»» i s) 3G(5=m) ΓΟ CO CO co ^ ro cn 〇 )N /*—> S (CO C£ CO 〇2 mmmm ^"ma mmmm CJ to i/> ^ M ς,Π ^ ^ '*—^ ·»—<«· 251I.S) 02(3=s) 33(3=s) 25(l=s) 08, 5. 09(2ll.>Bq) 5 ) •打· •綠.
經濟部中央抹準局印$L a B!a{i) 3/ζ ; 9191 53珀(ΡΛΒ)3/ζ ; scmlr nrp. 17-J〜17CO。。 (四召§|二-3群卽) σ cr a Ψ W_〇v 297 公发) -16 - 199098 A6 B6 五、發明説明(14 )
-a^ CO 〇 r〇 -^1 CS ¢-3 05 Ο ), 0—<> y~s S /^—s (cn 一 c«3 co o • 〇 - C~* C~* Γ™ CO 〇 M M M P〇 <·"» 'w^ Nw*· N·^ »wX CV2 C.
•O 2. s(fi=s) 2.95(3=s) 3. 31(3=0 4· 35(l=s) G· OG(ll-s) 7. 19/7b(10=m) ^ --J O CO CO CO cn co =)^―1» /«—N «<—·>» /***·» • ( CV3 ►— CO CO mmm ___ Vw^ ··»»-- ◦ >> ⑺ Μ 0Ί c/> —J cn S—✓ -w» V—<· V—✓ 5 C5 -a>^ O -3*» C-5 CC l\3 • >— O CO O CO CT> 05 ) κ-~\ X~S y—«\ <—n CO ( CV3 一 OJ C*; C·)
CO CJ1 > V» Vi V» • —«j :3 Nw··、✓、《✓、》✓ “ · ·〇 cn w v · ~ - CO CO
ND 打 綠 經濟部中央揉準局印裝 b c 尨al(FAB) m/z : 929〔mlr 趑»(ΡΛΒ) πι/ζ ; 953〔HI1〕_ a cr 甲 4(210X 297 公廣) 一 17 一 189088
A B 五、發明說明(15 ) 經 濟 部 中 央 搮 準 局 印 甲
1—» A t—1 u> 1—1 to J—4 1—1 I - 1 o 1 〇 1 o cCT ο ro" o C\J ΓΝ3 丄 ifV7 Λ 力 u kA. I T ° 1 c~> cT to - cn co to ro tvs CTi CO CC P〇 CND CJl CO PO ΓΟ —j co co ro CO O CJ O CO to CS CO 〇 C〇 C-2 cn co 〇 cs -=^ λ. cn co iw r\D • 〇 二 c〇 ►— 一 —-J o co o ro cn co cn 么 ). X—\ S (cn C-O CO cr> cr> \ X—N. /<—S V \ (CO CO o o 〇 ) - /-~s κ—S V —j ( cn *— co co CT3 (OJ C-O C75 -j · =: iz = r= 7° F F } · =:= 一 一 (· cn ^ · · ' • * Ml I _ aw PO CVS to on M to 〇 #«—«v >—✓ %_✓ v—> f«〇 i/i ΧΛ Vi Vi /•"•y >—/ *»-✓ ^w* >-✓ co tn ^ m ^ (Λ • ςη 产,》 ΓΌ \n \λ ^ r~S s^·/ Vw/ \ ΓΟ CO 二 ««*>· CO ►— * CO ^ —j r= C£ ~ > 3 =3 H —j y > r= CO 33 i c_ >t c_ • If a〇 to ►— V^/ 飞 P P P m to m {請先聞讀背面之注意事項再填寫本页)
97 2 X 8 199098
A B 五、發明説明(16 ) 經濟部中央搮準局印狀
00 h-4 H-* »—1 U1 I· ο 1 〇 ΤΓ 〇 ό I o G 1 o 〇 rS* rs :¾ CO CO 1 〇 pc' ό ό - 工 kaw« = -O CT CT CO CO ΡΟ cn〇 tn ro co c-J ο ς〇 cn oj )~ 1 /«—n y—s (CT5 ( CO CO CT5 -j ♦ cn =— • cn · ' ^ ' C*) to Ui (Λ PO X—\ 'w/ cn = 一 zr '―^ rr * >w/ on 〇j co cnj -*0 O CJ O C"5 CO CS5 ω CN3 *N * ·»—S· *N \ CNi c^t CJ C£ ^ <· ¢3 * · * C/1 CO 沾的的 V—✓ 'w* >«—✓ ro k 匕 II ►— n" cn co co tv3 ro end ro w-c^toococccvsro ►— core—JCNSOCnCO , \ *>—V i*—\ ✓—>k /^N y—w /*"*V cn>— COCOCTiC^COC^ • t - · · · ^ ^ ^ C〇 in in Vi t^i (/1 y>-m^ 、.- -* w——t Sm/ %w/ v«^ ΓΟ > S3 «_·> 11 f\3 ? NW* -j cn λ· co co evi cj 〇 to 〇 ro CO O 〇 CNJ CJ o cc • ( cn — CO CO C"5 S . 二=== w · 〇 - ' ' ^ ΙΛ iA iA tA CJ3 ^»*~Ν »»«✓ 'W# >W» Nw» - re ZZ > -J cs l子 —J c— • 11 C"> λ- ro N v^/ < Ϊ3 二 a CJS 1 CO > CJ , 03 /—1 三 U-< 十 P 紲 2 (5 ......................................................¾...............................^..............................# {請先閱讀背面之注意事項再填tr本页) -19 - 199098 A6 B6 五、發明説明(17 ) 2 2 2 1 2 0 19 -c=2l^-c=3
Λ-ζο-一。-Cl-HQ J 0112 h {請先閱讀背面之注意事項再填荈本页) 裝 Π: m w rc ro co ς〇 ς〇 css ro μ— CO to O CO ro pc cn cn cc _ · «v /—S \ -J ^ C-£ C-£ ω 2 t^· - * · "· » CO C3 vi Vt (Λ v% i/i , *«—N V—✓ V»·*·» V««^ Sw» V—✓ —4 ro 乙·= CJ > ,C3 二 ro --J II > H— 35(G=S) 33-l-s) 2(3=s) 32(311, s) gull- s) 98, 5. Qo(z=gq,v12llz) 09/7. 29(=, m) S(G=S) 3-K31I.S) 02(3=s) 32(3=5) 57(1=5) 03, 5. 0G(2ll>Bq, V11HZ) 13〜7_ 35(=, m) S(GFS) 93(3=s) 31(311. s) 27(1=:0 Ί1. 5. 4G(2II,>一 q, V121IZ) i5/7.s;(5=m) 2 § ίτ..............................練 經濟部中央橾準局印裝 N* 彐一 cr 甲 4(210X 297公《) -20 - 經濟部中央搮準局印焚· 1990S8 A6 B6 五、發明説明(18)
to to U1 to 厶 to ω |· ο ότ o ΓΌ & -n 1 o Φ i o 5 o 6r; - Π: :r cn Λ. CO ΓΟ ^ Ο ο 么 CO ΓΌ λ. ο co in ς〇 •一 C ro »— co c-: CT3 t/i 6Λ t/i CO C3 ·*—✓ '»—✓ ,Λ —J 'W> CSD / —J cn co co ro n CO CO O CO ^ ΓΌ O CO ·ΐ>» O ) , /-—s r—S <«""S , (cn c-〇 c-J crs 3 -*4 ·==:二= ·〇·'*· ►— C\3 ΙΛ ν*ί ΓΌ y—S ·»—✓ ^ Ί—»» N—^ , ro CO > cn 35 L已 -o CO CD 05 ^ CO U3 tN3 C3 ¢0 cn CJ 〇 CO CD cn cc ro co C3 )- S />-^ N ^-s { -=^ ►— CO C-2 CT5 ^ ^ i==== 〇 —J Μ (Λ V) M ^ / v—✓ • CN3 =: - ro > CO Z3 l ^ -*J <— * II U3 — -JO ' zzz N rr ^ V_^ tn ^ co co ro cj ro 二 co o ro 二一 C〇 公 C3 )S κ—N r**s (ro *— cj co cd CT5 >· ΙΛ n 4Λ cc CS? '—^ ^ ^ v—✓ <*—N Λ ^ ^ 3 P P ......................................................St..............................^..............................#!.{請先聞讀背面之注意事項再填寫本页) -21 - 甲 4(210X 297公*) 199098 A6B6 五、發明説明(19) 經濟部中央搮準局印¾ to ISJ CO E" * 1 〇 ro" ά ζ ο t\3 o ΖΣ. 〇 ΓΌ O w-j-4 = co cn co co ro >—tn CO CO O CS5 o »— cj^ ro —j ) )· /«—N \ N ( (CTJ C-3 C-J CD ===:=: = t\3 CJ> CO t/» M w CJl -*>J ^ <—N CO rc ro == r- c— > 3 2 C3 s·_<* V·_/ 二 II N— cc N v_^ go co -j co ro ro 〇 ^ CO O CO Ο O ->J C-5 Ci: O - , V /—X CS CC C-J CO CT5 CS CO ™ C\3 t/t (Λ bo /*—V 零 V 一 CO 一 N_^ CJ GT «-*s Nw^ —j cn co ro rc -5-. e3 CO C3 CO CO —J cn CD CO ( (CO CJ ->«J *~-J —^ zz ······ CO (Λ <Λ M ς/ι v^/ s—^ n—✓ S cn co 3 3 -0 CO to ΓΟ —4 O CO O CVS * CO O CD C£5 ) s /«—s U3 ( C5 CO --j == n =: -j · ' · * • »>·« Μ (Λ (/> cp ^»· V—✓ >—✓ c〇 , /*~N —-3 二. ZZ — ' CS 己/ —J cn a a a 0. 2 ( ? ......................................................it..............................iT..............................#*. {請先閱讀背面之注意事項再填¾本页) f 4(210X 297公辞) -22 i99〇98 A6 B6 五、發明說明(20 ) 3 3 3 2 3 1 3 0 IC112
a c=2-n a° IC=2C1I21
-Cl-K
(請先閏讀背面之注意事項再填寫本页) ·«._
H
H
H
H 0 —co co cj co ro ^-· ( *—^ )- y—S ✓—N /—N (cn cj co CT5 CN5 V5 «λ V» to '«w^ v CS5 CO =: c.
> C3 -D cn co co co to 35 tS 一 — CO y—N r—~s. y^N «κ—N r〇 C.5 C-3 o
一 ◦ co <〇 ro ^ oj co cn cs )y—s <«—»v y—»\ y—S (►— 05 CJ 25= 11(3= 33(3= 41(1 = 31, 5· 49〜7 GG/7 05〜Η s)s) s) s) s) 95(=,3)
CO Ln (/) ΙΛ ΙΛ C^O 3 32(2=ABq) 5G(2i=m) 73(217) 19(211,3) i) .打. •綠. 經濟部中央搮準局印製 甲 4(210X297公沒)
O
P cr -23 - i99088 A6B6 五、發明説明(21) 經濟部中央搮準局印裝 Ό) 10 CN U) Ul 1 o CN3 ό 1 o ro -3 二 Π: 二 co co rc ro cj o tn cj cn ►— / L· L —4 · · · • O -=^ cd σ> fc— <—s> /-"s x CJ C*5 CO =:=:== =-W^ ✓ V—X -j cn co co m 〇 〇 CO O -5*» CO 〇 OJ — )/—> /<—s /*—s · (►— cj c-i ro « ·— ·—~ · ~«j ——— • » « - ζ_Π {Λ ίΛ «Λ CT3 ^ N_✓ S._✓ «*»«✓ y— g p rc s = ·>_✓ ^ CO CC CO CO <=> CO t\3 CJi CC X—> ^-*N >—> C£ CO ^ μ ς〇 、—) cri -a- ω c-: rc c_n ^- 〇 ¢7¾ CO ο ΓΌ f~~*> nm <**~> Cp*2 "«J cs )^-S * /·-^ -S. <—X (CSS CJ1 c»0 C-3 C"> • '_^ * * ~ CH CO «Λ V» ν» «Λ «a*» '~v s—✓ ·«—✓ v—/ —J ΓΌ L-^ · —— =ro广 -· o > 2 )二 w (二 - * ^ tl 一一 y^-N Γ〇 cn :n =N , Sw^ a v_x cr cr P σ 2 § ......................................................¾...............................打 {請先閱讀背面之注意事項再填寫本百) 甲 4(210X 297 公兮) -24 - 199088 A6 B6 五、發明説明(22) 經濟部中央抹準局印裴 A Η-*· 〇 ω VO CO /=pG~ yi- sz o o CO ό rt· ►— · cq o c 0' t〇 〇· h—t /=^ O — 2 1- 〇 1 o >-H to 2 2: = —o cr; cn co rc ro ro —j co rc cn t-2 **J rv5 ro cs (►— ·— C£ C£ 2 _丨 J rn^m m «— — — 二》;Λ t/> </> 的 f S_x «w» N—^ ✓—>s cn " 3 -J CO tS3 一 cc o ►— o )\ (2 J zc C3 ^ ►—· cn 3 —J -J 各 OO ΓΌ Cs3 cn ro css cj CD cj CTi C-D ►— CO CO CO \ i y—K -S. s ((ro to co *~J * J ιι·ι· IMW W> CT> CN3 ΪΛ (Λ 1Λ C\5 CO w v—«* n_x 'w*· /—V /^*N t— ·—· u === 3 2 N~ '-•X S-✓ CS -J cc ω ΓΟ 〇 ^ cj ►— rs: CC —J ^ o o 1 1 <—S X—X <—N C ( CJ OJ 〇 CO -J 2= ~ fs3 C"> ίΛ 的 z f〇 >-✓ 'w/ %»✓ «Sk> 3 B >W» ·«-✓ Ϊ3 -N·速 Ξ 5 〇 so cn '― r—i *-s cr ......................................................K-..............................ir..............................冰, {請先閱讀背面之注意事項再填苒本頁) 甲 4(210X 297公辞) -25 - 199098 A6B6 五、發明説明(£3 ) 經濟部中央揉準局印装
U) A NJ 1 〇一〇 〇 c*3 ό 1 o t\3 rr -0 CO CO CN3 • · · · —CO 〇 C-5 CO *2» C? U (CO CJ -4 = . =r • - ►— · “ ς〇 一 t/t CT> 'w* ✓—> V CJ S£3 = 、 %Λ 3 一 —j cn ω co ro 一 * N * * *— ΓΟ >— CO O CO -=>-= 〇 CO ►— CJ C«3 (> cn CJ C-5 c=: ·==:== • -s , - ,- · , _=*. · —j tn ΙΛ 5Λ '>^-/ N—^ ^ s > =fl -- 一 3 co CO N* 07 二二一二 Gf. “ 一《4 —| j 一一 — 一 <«-Ν ζ_Π。CO ~η — ^ ,'- <L3rccor〇rocn--jx: zz ^ J -=^ ^ ^ f\j • . · coc^cjcn·^: — ico^-N ^ cn N -J · · · . Ξ N 1 — π 益 現二 ---«Pf=pr-〇z- - =m -s*. cn —j ^ ^ ^ ·—^ / 〇〇λ.^— 〇—=··*^ ^ 1 • · · ro r〇 -^4 ^ ·--! co 〇 三— c〇 p p p ^ —匕〜二 ' 屋;q cn 〇j ·— - P {請先閱讀背面之注意事項再填窝本页) .¾.. .打· .綠· 甲 4(210X 297公 26 199038 A6 B6 五、發明説明(24 ) 經濟部中央橾準局印製 KTi 1 〇 CO Λ c= 口 -ι I Ο NM to 力\ 0^-0 ^-¾ rra 1 o 0 1 o O tN3 〇 Cl cIT 二 X s- N=*2: ω co ro CJ O CO o cc cs i X—N -J CO 0¾ cn广^广 CC 5Λ (Λ Nw〇 V—/ CO 2 co co ro ro co »— co O -a- O --J S, #-~N /^«v ΓΟ CO to C2 ΙΛ ΙΛ to 5Λ s_X v_^« CJ CO CO CO O 二 CO cc <=> /—-s /—s CO CiJ 〇 ΙΛ 的 t/> S_✓ Vw^ s—/ cr> cn ω co ro r\5 cc 二 co ο ω ro «»· ro 〇 — cn cn y—S ^ X—N X - ^***V CS5 一 CO CO ΓΟ C«5 广 r*· ·Τ- Γ- q Γ*~ tyt (λ \λ u» ς〇 ίΛ Ν_^ ^_Χ· *>W^ ν_^ <»—V C£ bo σ P cn {請先聞讀背面之注意事項再填寫本页) ·«.· .打. •線· 甲4(210X 297公沒) -27 199098 A6 B6 五、發明説明(25 ) 經濟部中央揉準局印焚‘
U1 ]—1 o v〇 CO -(CII2)3-i{3-{3 > 1 o CnT &; CO 1 o CS3 -(cii2O - 工 2. 33(011. s) 3. 00(311, s) 3. 33(311, s) Π. 59~G. 71(211, m) 7. 心卜7.Γ)1(川.m) 8. 17~B.21(111,n.) 2.27(311, (1) 2. 3C(GII. s) 2.98(311, s) 3.32(311,5) 5. 07(211, m) Γ). 95~7. 25(311, m) 2. 2iJ(fill. s) 2. 90(311, -0 3. 32(311, s) 5. 20(211. m) fi. 95~7. 30(311, n.) 2. 3i)(f.ll, s) 3. OCCill, s) 3. 33(311, s) 7. 11~7. 32(511, m) 質贵(ΡΛΒ) m/z ; OGCtMin' I R(Kllr) cnr1 ; 343G, 1734 5¾ 贵(ΡΛΒ) m/z ; 885[ΗΙΙ〕+ I R (Kl)r) cm-1 ; 3Ί36, 1735 m_P. 〗fi3〜IGf/C (自乙6?.屮W.结品) SW(FAU) m/z ; 905Π1ΙΙ31· I R(KBr) cnr1 ; 3470, 1734 P P 紲 2 (豌) ......................................................¾..............................^..............................& {請先閱讀背面之注意事項再填寫本頁) 甲 4(210X 297公犮) -28 - 1990S8 A6B6 五、發明説明(26) 經濟部中央棟準局印製
νπ U1 υι Ui to • Λ Λ ! 〇 £Ν3 Q ο 1 ο 2-p CH2PH Φ 〇—0 Q 5 Ό P :o2ch3 - 工 二 cn -a- co co ro — ς〇 c〇 Ο CO co ro c*? ο } \ ** N <»—N —>3 CS3 =*» CJ CJ -o to co ro —cs 0 co 0 ro 0 CD CS CN3 — <〇 (· \ -^4 cn ro cj cj 2. 43(G1 3. 0Γ>(3Ι 3. 31(31 3. 01(31 5. 04, 5. 7. 38~0. ΟΊ, CO · ,~ CO ιλ CJl <yt ίΛ <<—S /^-N >w^ ^ cc rvs CO 0 - ~, - ~- CC 4 «Λ <Λ «Λ V> N \ crs ro 〇 1— - ^ ~ * CO 〇 V» 4Λ ΙΛ ^ y—*V /^-S. N—^ N—✓ '«―/ Sw/ co ro s > 'w*» 二 <— > C II ro 2 > 33 J3 c_ > s II b—· ro N 3 > w r=i «— > c u · ►— C-5 n" V—✓ Πΐ·ρ. Ill〜113X: (自己烷屮Fi結品) 質贵(FAB) m/z ; 9S):3〔HII〕+ I R (K13r) cm-1 ; 3/130. 1734. 1G13 丨 m. p. 1G8〜17CTC (自甲醉屮W結品) 質贵(ΡΛΐυ m/z ; 9C31HUV I R(KIk) cnr1 ; 3457.173G m. p. 137〜13JTC (自φβ?屮ra结品) 質贵(ΡΛΒ) tn/z ; 101Γ,[ΜΙϋ + I R(KQr) cm-1 ; 3^(5, 1730, 1G73 IGOi) P (請先聞讀背面之注意事項再填寫本頁) •裝· •打· .綠· 甲 4(210X297公发) -29 - 199098 A6 B6 經濟部中央搮準局印裝
五、發明説明(27) ΟΙ CO U1 Ul Ul Ul • 1 〇 A -η -Π Λ - (Cn2)“Q> -CH2-^>-C3ll7-i 二 工 二 2. 3KGII, s) 3. 07(31!. s) 3. 33(311, s) <1. 9Γ). Π. 02(211, ABq. JA»=13llz) G. ()ίί~Π. 76(111, n.) 6. 00~G. 8B(2li, m) 2. 29(011, s) 3. 02(311, s) 3. 33(311, s) 5.07, 5. 15(211, ΛΒη, JAD=13l!z) 7. 10~7. 50(-111. m) 2. 32((511, s) 3. 06(311, s) 3. 33(211, s) 7. 13~7. 30(511, m) 2. 29(011, s) 3. 04(311, s) 3. 33(311, s) 4. 9Cu 5. 02(211, ABq, JAd=12IIz) 7. 1!)~7. 32(411, m) m. p. 129〜131°C (自甲S?中ΓΪ結晶) 5¾贵(FAB) m/z ; Βϋ9ΠΐΙΙ]'' I R(KI)r) cm-1 ; 3473, 1733.1G28 m.i). 131)〜141°C (Qtpg?屮Fi結晶) ma (FAR) m/z ; 931CHII广 I R (Ktlr) cm-1 ; 34Π4, 173Ί m. p.卯〜98°C: 質贵(FAB) m/z ; 〇95[MII]' I R(KBr) cm—1 ; 345G, 1735 m. p. 149〜ΙίΗΧ: (ΘΦδίΨΡί結品) 質慑(FAB) m/z ; I R(KIU) οηΓ1 ; 345«, 173G.1G32 P P (請先聞讀背面之注意事項再填"本頁) .裝. •打· •線. 甲 4(210X 297 公韙) -30 - 199098 A6 B6 五、發明説明(28 ) 經濟部中央搮準局印裂
Ο CO H-* 〇 ΟΊ o i * 〇 ά 1 ^ 1 o ότ 1 -π 1 o ro 0 1 o ro Φ e 二 二 —J -¾. OJ CJ CN3 O CS CO O CO 一 ro cj tn 一 i ’ S /—V. -¾. CJ CC CT3 CV3 O 〇 CO ΪΛ (Λ ⑺ y^—S /—s ✓ N—✓ c£ ro ik > s π CJ 'w, —j cd c-π co co ro co —j o ro o co —j ro co ο o { 1 /—s v <»—s y«—v —J C"> ΓΌ CJ CJ· C·? co ς〇 -3--,, ς〇 〇 ν*ι v> ιλ N \ Ν»✓ Vw» CO Ξ 3 ν_^» V_^ -^j -^J Λ-. co CO CN5 C3 CO O CJ cn cs co c*5 cn cj { J , y-~v y—N X —J 二 CC CO C"> cn ro cn ~ ~ ~ 〇 ju. CC ut bo to jsi c\3 ro 3 3 > '«✓ ZS r> c^_ > c II . »—· ro ?7 s_^ —0 A* CO to C\3 Cs3 <J5 CJ o ro cn cj cn ts { , s s s in CO C£ 2 CO o c_n ►— μ m 的 ^―s κ—S '—^ N—<· w« -=5- ro 3 > ^ C3 二 t— > 二 i! ro N VwK 1—1 -—· ψ S2^e: -§ -N琴己 —i re , ΤΓ Cn5 —j 一 S > —* ) co 52 = ^ ( co 〇 ° w -3 二 trTu _ 丨 ZC =2“ Ξ.:5 -cl cn + ? 1— * C3 ^ · -T1 CO —-i > -r zj^Ss a / ^ n ^ :¾ ^- • 2 广, Πίτ <» .1 —*"l ZS =Q 〇 -= ^ri ro _ · w 、J ΓΟ 十 Pgr. 5 1^ fsl |? g 9 二 m ^ 1 ^ P0 〇 -Γ5 已 d 十 *—h r ^ ~ 5 尨·? 兰一;r戒 —*j ✓*> -—^ ►— , ro ^ i; f^5 2 / CO π 〜 — cj H ^ ro 1 ΖΣ. ^ ,:5 cl P (Ϊ (請先閲讀背面之注意事項再填坏本頁) •裝. •訂· •線· 甲4(210X 297公沒) -31 -
1990SB A6B6 五、發明説明(29 ) 經濟部中央捃準局印裝
U) -1 OCII2CF3 -cu^-(j 1 o ΓΟ 二 3. 00(311, s) 3. 33(311, s) 5. 13(211, s) G. 79(111, dd, J=Gll7., 31!z) 0.95(111, d.J = 3llz) 8. cJ, J=G)lz) 2. 3KGII. s) 3. 03(311. s) 3. 33(311, s) 5. 00, Γ). 05(211, AlUi,JAn=13ll7.) fi. y 卜7. 120丨UO ------ m/z ; 952CHII]'· I R (Kl]r) cm-1 ; 3-M6. 1734 m. i). 134〜13G°C (自中17+結品) 踅贵(FAB) m/z ; 889[HII)h' 1 R(KIir) cm-'; 3470. 1734 cr P (請先閱讀背面之注意事項再填寫本页) •裝· •打· 甲 4(210X 297公沒) -32 -
Claims (1)
199088 A 7 B7 C7 D7 六、申功專利範園 附件二:第79108273號專利申請案 中文申請專利範圍修正本 代表 公告 民國81年2月修訂 6 — ◦一甲基紅徽素A 9 —B衍生物,由下式
(請先閲讀背面之注意事項再填寫本頁) 經濟部中夬標準局員工消費合作杜印製 其中X是苄基,在苯環上被選自下列1至5成員基圍所取 代,包括鹵原子,C2-5烷基、硝基、三氟甲基、苯基、 笮基、苯乙烯基、2—氯苄氧基、3— (4一氯苯基)一 1, 2, 4 —腭二唑一 5 —基及2 —甲基羰基笮醯基;經 1至3個硝基取代之苯基;α —甲基笮基;α —甲基苯乙 基;二苯甲基;三苯甲基;二苯駢環庚烷基;下式一( CH2 ) n - R基圍(其中R是苯基、苯硫基、被1¾°原子 取代之苯硫基、C5-5之環烷基、棻基;Μ基、瞎啉基、 〇 苯乙烯基、正葙基、5 —氯—2 —卩塞嗯基、2 —笮氣羰基 木紙張尺度適ffl十闲闼家捃-!MCNS)'P4规格(210x297公釐)_ j _ AT B7 - 六、申請專利範® 胺基DS唑一 4 一基,酞醯亞胺基、9 一溴_9 —葙基、1 一烷氧羰基甲基蚓跺一 3 —基,其中為C;-3烷氣基、4 一(吡啶一2_基)哌嗪基或被1或2成員選自鹵原子所 取代之吡啶基及2, 2, 2—三氟乙氧基,且η為1至6 的整數),Υ是氫原子,及其藥學上可接受之鹽類。 2 .根據申請專利範圍第1項之化合物,其中X是笮 基經Ci-5烷基或鹵原子所取代;或下式—CH2 ) η — R基圍(其中R是葸基,且η是1至6之整數)。 3 .根據申請專利範圍第1項之化合物,其中X是Μ 基甲基、2, 4, 6 —三甲基苄基、或4 —(第三,丁基 )苄基。 - (請先聞讀背面之注意事項再瑱寫本頁) •R. 綠. 經濟部中央標準局員工消費合作社印製 木紙張尺度適Λ十raw家樣準(CNSVfM规格(210x297公釐)-2 -
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP26279789 | 1989-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW199098B true TW199098B (zh) | 1993-02-01 |
Family
ID=17380743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW079108273A TW199098B (zh) | 1989-10-07 | 1990-10-02 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5302705A (zh) |
EP (1) | EP0422843B1 (zh) |
JP (1) | JPH03204893A (zh) |
KR (1) | KR910007953A (zh) |
AT (1) | ATE118503T1 (zh) |
CA (1) | CA2027074A1 (zh) |
DE (1) | DE69016912T2 (zh) |
DK (1) | DK0422843T3 (zh) |
ES (1) | ES2071036T3 (zh) |
TW (1) | TW199098B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0260938B1 (en) | 1986-09-18 | 1992-12-09 | Taisho Pharmaceutical Co. Ltd | Erythromycin a derivatives and method for preparing the same |
EP0775489A4 (en) * | 1994-08-12 | 1998-05-06 | Taisho Pharmaceutical Co Ltd | INTERLEUKIN-5 PRODUCTION INHIBITOR |
IT1276901B1 (it) * | 1994-12-13 | 1997-11-03 | Zambon Spa | Derivati dell'eritromicina a 9-0-ossina dotati di attivita' antibiotica |
US5872229A (en) | 1995-11-21 | 1999-02-16 | Abbott Laboratories | Process for 6-O-alkylation of erythromycin derivatives |
US5929219A (en) | 1997-09-10 | 1999-07-27 | Abbott Laboratories | 9-hydrazone and 9-azine erythromycin derivatives and a process of making the same |
PT941998E (pt) * | 1998-03-03 | 2004-12-31 | Pfizer Prod Inc | Antibioticos macrolidos do tipo 3,6-cetal |
HRP980189B1 (en) * | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
CA2292359C (en) | 1999-01-28 | 2004-09-28 | Pfizer Products Inc. | Novel azalides and methods of making same |
AR023264A1 (es) * | 1999-04-08 | 2002-09-04 | Hokuriku Pharmaceutical | Derivados de eritromicina |
KR100428703B1 (ko) * | 2000-02-02 | 2004-04-30 | 한국과학기술연구원 | 헬리코박터 파이로리의 성장 억제 효과를 지닌 신규 마크로라이드 화합물 |
US20090054634A1 (en) * | 2007-08-09 | 2009-02-26 | Vinod Kumar Kansal | Process for the preparation of clarithromycin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2473525A1 (fr) * | 1980-01-11 | 1981-07-17 | Roussel Uclaf | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
US4331803A (en) * | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
JPS60214796A (ja) * | 1984-04-06 | 1985-10-28 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシン類の製法 |
JPS61103890A (ja) * | 1984-10-26 | 1986-05-22 | Taisho Pharmaceut Co Ltd | 6−0−メチルエリスロマイシンa誘導体 |
EP0201166B1 (en) * | 1985-03-12 | 1990-02-07 | Beecham Group Plc | Erythromycin derivatives |
GB8506380D0 (en) * | 1985-03-12 | 1985-04-11 | Beecham Group Plc | Chemical compounds |
US4670549A (en) * | 1985-03-18 | 1987-06-02 | Taisho Pharmaceutical Co., Ltd. | Method for selective methylation of erythromycin a derivatives |
JPS63107994A (ja) * | 1986-05-02 | 1988-05-12 | Taisho Pharmaceut Co Ltd | エリスロマイシン誘導体 |
US4740502A (en) * | 1986-06-20 | 1988-04-26 | Abbott Laboratories | Semisynthetic erythromycin antibiotics |
EP0260938B1 (en) * | 1986-09-18 | 1992-12-09 | Taisho Pharmaceutical Co. Ltd | Erythromycin a derivatives and method for preparing the same |
KR880009960A (ko) * | 1987-02-24 | 1988-10-06 | 데이빗 로버츠 | 화학적 화합물 |
-
1990
- 1990-10-01 US US07/590,805 patent/US5302705A/en not_active Expired - Fee Related
- 1990-10-02 TW TW079108273A patent/TW199098B/zh active
- 1990-10-03 JP JP2265812A patent/JPH03204893A/ja active Pending
- 1990-10-04 DE DE69016912T patent/DE69016912T2/de not_active Expired - Fee Related
- 1990-10-04 EP EP90310923A patent/EP0422843B1/en not_active Expired - Lifetime
- 1990-10-04 ES ES90310923T patent/ES2071036T3/es not_active Expired - Lifetime
- 1990-10-04 AT AT90310923T patent/ATE118503T1/de not_active IP Right Cessation
- 1990-10-04 DK DK90310923.9T patent/DK0422843T3/da active
- 1990-10-05 CA CA002027074A patent/CA2027074A1/en not_active Abandoned
- 1990-10-06 KR KR1019900015911A patent/KR910007953A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPH03204893A (ja) | 1991-09-06 |
DK0422843T3 (da) | 1995-04-03 |
ATE118503T1 (de) | 1995-03-15 |
CA2027074A1 (en) | 1991-04-08 |
ES2071036T3 (es) | 1995-06-16 |
EP0422843A2 (en) | 1991-04-17 |
US5302705A (en) | 1994-04-12 |
DE69016912D1 (de) | 1995-03-23 |
KR910007953A (ko) | 1991-05-30 |
EP0422843A3 (en) | 1991-09-18 |
DE69016912T2 (de) | 1995-07-06 |
EP0422843B1 (en) | 1995-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW199098B (zh) | ||
JP4669607B2 (ja) | 抗微生物キノロン類、その組成物およびその使用 | |
Foroumadi et al. | Synthesis and antibacterial activity of levofloxacin derivatives with certain bulky residues on piperazine ring | |
Xu et al. | 1H‐1, 2, 3‐triazole‐tethered 8‐OMe Ciprofloxacin and Isatin Hybrids: Design, Synthesis and in vitro Anti‐mycobacterial Activities | |
Lahari et al. | Design and synthesis of novel isatin derivatives as potent analgesic, anti-inflammatory and antimicrobial agents | |
JP2017523197A (ja) | 2−ピリドン部分を含む選択的抗菌剤としてのアリールヒドラジド | |
CN114437109B (zh) | 一种十字孢碱卤代衍生物及其制备方法与应用 | |
Guo | Design, Synthesis, and In Vitro Antibacterial Activities of Propylene‐tethered Gatifloxacin‐isatin Hybrids | |
KR100196440B1 (ko) | 항균제로서 유용한 7-치환-6-플루오로-1, 4-디하이드로-4-옥소-퀴놀린-3-카르복실산화합물 | |
Sokol et al. | Transition metal-catalyzed synthesis of new 3-substituted coumarin derivatives as antibacterial and cytostatic agents | |
Suma et al. | Synthesis and antibacterial activities of N-phenylpyrazolines from veratraldehyde | |
JP2000513378A (ja) | キノロンカルボン酸誘導体 | |
RU2636751C1 (ru) | Антибактериальные средства на основе производных ципрофлоксацина | |
Ashok et al. | Microwave Assisted Synthesis of Flavonoid Based 1, 2, 3-Triazole and Isoxazole Derivatives, Their Antibacterial, Antioxidant, and Anticancer Activities | |
JPS63132891A (ja) | 三還式化合物 | |
Leite et al. | Synthesis, in vitro and in silico studies of indolequinone derivatives against clinically relevant bacterial pathogens | |
JPH02292289A (ja) | 置換アゼチジニルイソチアゾロピリドン誘導体、その製造法及びその医薬用途 | |
DE69428206T2 (de) | Chinolincarbonsäurederivate und ihre salze | |
TW584632B (en) | 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions | |
M Abadleh et al. | Synthesis and Biological Activity of Some New N1-(6-fluoro-4-oxoquinolin-8-yl) amidrazones | |
Shafiei et al. | Synthesis and in-vitro antibacterial activity of N-piperazinyl quinolone derivatives with 5-chloro-2-thienyl group | |
Shafiee et al. | Synthesis and antibacterial activity of N-[2-(2-naphthyl) ethyl] piperazinyl quinolones | |
JPS6270370A (ja) | キノロンカルボン酸誘導体およびその製造方法 | |
Arshad et al. | Synthesis, structure elucidation and antibacterial screening of some novel 1, 3, 4-oxadiazoline derivatives | |
TW308587B (zh) |